Abstract:Ethnopharmacological relevance Zhi-zi-chi decoction (ZZCD), from "Treatise on Febrile Diseases", is a typical traditional Chinese medicine herb pair, which consists of Gardeniae Fructus (GF) and Semen Sojae Praeparatu (SSP). In clinical research, ZZCD was widely used to fight depression, remove annoyance. Many studies have reported that gut microbiota is critical target for the influence of depress through gut-brain axis, and our previously studies have found that ZZCD exhibiting antidepressant effect was through the gut-brain axis. However, the specific mechanism by which gut microbiota mediates the pharmacokinetics parameters of active compounds from ZZCD during the process of depression treatment has not yet been studied. Aim of the study To explore the differences in pharmacokinetics characters of bioactive iridoids from ZZCD and study the changes of gut microbiota at different stages of depression with the personalized medicine of ZZCD. Materials and methods A new strategy exploring the relationship among disease phenotypes (D), intestinal microbiota (I), enzymes (E) and traits of metabolism (T) named as "DIET" was established. Firstly, a fast, selective and sensitive ultra-performance liquid chromatography coupled with tandem mass spectrometer (UPLC-MS/MS) was established and validated to quality the main bioactive compounds from ZZCD and compare the pharmacokinetics and bioavailability of different iridoids prototypes and metabolites from ZZCD between normal and chronic unpredictable mild stress rats. Subsequently, the activity of corresponding metabolic enzymes of anti-depressive compounds, β-glucosidases and sulfotransferases, were analyzed by ρ-nitrophenyl-β -D-glucopyranoside and sulfotransferases ELISA kits, respectively. Finally, 16S rRNA gene sequencing was adopt to analyze intestinal bacteria composition for the treatment of depression by ZZCD. Results The antidepressant effect of ZZCD was promoted due to the increased exposures and reduced eliminations of anti-depressive compounds, especially geniposide and genipin 1-gentiobioside, under the depression state. With the ZZCD treatment, the depression was improved, but the exposures of anti-depressive compounds from ZZCD gradually decreased. Meanwhile, there were the corresponding decreased trends on the activity of β-glucosidases and sulfotransferases. With the consumption of ZZDC and the improvement of depression, the exposures of anti-depressive iridoid glycosides decreased and the activity of metabolism enzymes restored. Meanwhile, the dysbiosis of pathogenic bacteria ( Bacteroidota ) induced by depression was ameliorated and the probiotics ( Firmicutes ) at the phylum and genus level raised, the two phyla are closely related to the production of β-glucosidase and sulfotransferases. Conclusions It is the first proposed that ZZCD could personalized to treat depression at different stages targeting gut microbiota and gut microbiome could emerged as a potential diagnostic and therapeutic biomarker in depression.

Depressive Disorder Prevention by DIET Crosslink: Diet, Intestinal Microbiota, Enzyme and Traits of Metabolism

Antidepressant-like Effects of Representative Types of Food and Their Possible Mechanisms

Depression-associated gut microbes, metabolites and clinical trials

Gut microbiota and its metabolites in depression: from pathogenesis to treatment

Role of dietary factors in the prevention and treatment for depression: an umbrella review of meta-analyses of prospective studies

Advances in Dietary Interventions for the Treatment of Depression-Related Symptoms

Nutritional aspects of depression

Depressed gut? The microbiota-diet-inflammation trialogue in depression

Diet and depression: exploring the biological mechanisms of action

Systems biology approaches to identify potential targets and inhibitors of the intestinal microbiota to treat depression

Review of research progress on intestinal microbiota based on metabolism and inflammation for depression

Linking What We Eat to Our Mood: A Review of Diet, Dietary Antioxidants, and Depression

Mechanistic Insights into the Link between Gut Dysbiosis and Major Depression: An Extensive Review

Deciphering the Gut Microbiome's Influence on Depression: A Community-Level Constraint-Based Metabolic modelling Approach

Plant-derived bioactive components regulate gut microbiota to prevent depression and depressive-related neurodegenerative diseases: Focus on neurotransmitters

The brain-gut-microbiota interplay in depression: A key to design innovative therapeutic approaches

Anti‐Inflammatory and Microbiota‐Regulating Property of Deficiency Tonic Medicines in Edible Traditional Chinese Medicine: A Promising Therapy for Depressive Disorder

Gut microbiota mediates the pharmacokinetics of Zhi-zi-chi decoction for the personalized treatment of depression

Prebiotics for depression: how does the gut microbiota play a role?

Does Dietary Pattern Make Any Effects on Depression?

Human Gut Microbiota for Diagnosis and Treatment of Depression